Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kestra Medical Technologies (KMTS) Capital Expenditures (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Capital Expenditures for 2 consecutive years, with $7.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures rose 63.37% to $7.3 million in Q4 2025 year-over-year; TTM through Oct 2025 was $26.9 million, a N/A change, with the full-year FY2025 number at $22.9 million, up 87.6% from a year prior.
  • Capital Expenditures was $7.3 million for Q4 2025 at Kestra Medical Technologies, down from $8.2 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $8.2 million in Q3 2025 to a low of $4.1 million in Q1 2025.